Kyverna Therapeutics, Inc. (KYTX) Investor Relations Documents

Kyverna Therapeutics, Inc. (KYTX) investor relations documents from the company's IR site: 5 presentations, 35 press releases; latest deck 2026-08-10. Read in-app with summaries. First-party data.

Investor Presentation – August 2026: Kyverna Therapeutics is developing miv-cel, a CAR T therapy for neurologic autoimmune diseases, with a BLA submission for Stiff Person Syndrome expected in Q4 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-11Press releasePDF Version
2026-08-11Press releaseKyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
2026-08-10PresentationInvestor Presentation – August 2026
2026-07-27Press releasePDF Version
2026-07-27Press releaseKyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
2026-06-22Press releasePDF Version
2026-06-22Press releaseKyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Sup
2026-06-03Press releasePDF Version
2026-06-03Press releaseKyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in
2026-06-01PresentationKyverna - Jefferies Corporate Presentation
2026-05-18Press releasePDF Version
2026-05-18Press releaseKyverna Therapeutics Names Greg Martini as Chief Financial Officer
2026-05-14Press releasePDF Version
2026-05-14Press releaseKyverna Therapeutics to Present at Upcoming Investor Conferences
2026-05-12Press releasePDF Version
2026-05-12Press releaseKyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
2026-05-04Press releasePDF Version
2026-05-04Press releaseKyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial O
2026-04-22PresentationKyverna AAN Conference Call Presentation
2026-04-21Press releasePDF Version
2026-04-21Press releaseKyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically
2026-04-20Press releasePDF Version
2026-04-20Press releaseKyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durab
2026-04-09Press releasePDF Version
2026-04-09Press releaseKyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
2026-03-26Press releasePDF Version
2026-03-26Press releaseKyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-05Press releasePDF Version
2026-03-05Press releaseKyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
2026-03-03Press releasePDF Version
2026-03-03Press releaseKyverna Therapeutics to Participate in Upcoming March Investor Conferences
2026-02-24Press releasePDF Version
2026-02-24Press releaseKyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
2026-02-03Press releasePDF Version
2026-02-03Press releaseKyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
2026-01-12Press releasePDF Version
2026-01-12Press releaseKyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conf
2026-01-05Press releaseKyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
2025-11-14PresentationKyverna - Jefferies London Conference Presentation
2025-08-28PresentationNeuroimmunology CAR T Franchise KOL Event Presentation - August 2025

KYTX overview · KYTX earnings · KYTX financials · KYTX KPIs · KYTX ownership · KYTX peers · KYTX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.